Friday, 20 Apr 2018

You are here

The RheumNow Week in Review - 5 January 2018

Dr Jack Cush reviews the news and journal articles from the past week on RheumNow.com.  

  1. Hospital pts have higher risk of Clostridium difficile infection taking PPI's, H2 antagonists, sucralfate, several antibiotics, including carbapenems, 3rd/4th gen cephalosporins, metronidazole, piperacillin/tazobactam https://t.co/qPcN28FJOx
  2. Claims data show HBV Testing in RA starting DMARD is low in USA (20.3%) & Taiwan (24.5%), US does >1HBV test (43.4% vs 16.3%) compared with Taiwan. MUST do HBsAg, HBcAb, HBsAb, HCV Ab before DMARDs/Biologics https://t.co/hsh9LhSyTi
  3. CORRONA RA Registry Study of 566 ABA initiators and 1715 TNFi initiators shows that CCP POSITIVITY predicted a good response to Abatacept but not TNFi. https://t.co/nljAnFK1ao
  4. From a Colombian Chikungunya Virus cohort; 33/103 pts were seropositive CHIKV and had chronic arthritis for 22 mos, mean TJC 5, SJC3. https://t.co/kIAw6B6Wew
  5. Medication Safety Tips: 1) Keep updated med list 2) Bring med list to all doctor visits 3) Fill same med w/ same pharmacy, same doctor 4) take as ordered; taking less is NOT safer 5) when Dr Prescribes one med, ask him/her to remove one med!
  6. Great animated TED video on knuckle-cracking and why it feels good. Thanks to Ai Lyn Tan! https://t.co/kdbisKNN6m
  7. Inequity in biological DMARDs uptake for #spondyloarthritis across the globe: results from the ASAS-COMOSPA study https://t.co/s6GgCGliiI @ElenaNikiUK https://t.co/uMzNeQZcbJ 
  8. Autologous stem cell (ASC) Rx looks favorable for systemic sclerosis (https://t.co/JK9oeg8bHC). recent safety review of 18 ASC pts showed 4 death shows a strong need to optimize Pt selection to reduce toxicity. https://t.co/1a7uvHOKur
  9. Stem Cell Transplant Succeeds in Scleroderma  
  10. Sorting Out the Complexities of Autoimmunity with Immune Checkpoint Inhibitor Therapy 
  11. Despite Increasing Metric Use, They Are Not Widespread in Rheumatoid Care 
  12. Bone Marrow Edema May be Found in Normals, Athletes and Military Recruits

 

Disclosures: 
The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

The RheumNow Week in Review – Vitamin D Snark Report (4.20.18)

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com.  A second life for Syk kinase, Vitamin D talk, VTE, regulatory hearings and the Lupus clinic edge.

RheumNow Week in Review - Do you Dig Shingrix? (4.6.2018)

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. Highlights includes manpower shortfalls, comorbidities in AA Lupus, certolizumab pregnancy safety, which Shingles vaccine is best and the power of combination biologics in severe refractory  SLE.

"Breakthrough" Drug Designation by the FDA

The current issue of the NEJM reviews the Food and Drug Administration (FDA) “breakthrough therapy” designation that was introduced in 2012 to expedite testing and approval of medications that were intended to treat serious or life-threatening conditions.  This status is granted when preliminary evidence with a new drug suggests substantial benefits over existing therapies for these unfortunate conditions.

ACR Projects Significant Manpower Shortages for 2030

Arthritis & Rheumatology has published the results of the 2015 Workforce Study of Rheumatology Specialists, and estimates a current shortage (demand > supply) of 700 (12.9%) full-time rheumatologists and that this deficit will worsen (102%) to 4133 FTE by 2030.

RheumNow Week in Review -The Temporal Artery Biopsy Letdown (4.6.2018)

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. News on the cost of RA care, infections on planes, CV events and Sacroiliitis in IBD, NXP-2 antibodies and calcinosis and rituximab in myositis ILD patients.